Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation

DOI: 10.1016/j.bbagen.2016.04.021

Authors: Paolo Ruzza (CNR-ICB-PD) , Rosa Maria Vitale (Institute of Biomolecular Chemistry of CNR) , Rohanah Hussain (Diamond Light Source) , Barbara Biondi (CNR-ICB-PD) , Pietro Amodeo (Institute of Biomolecular Chemistry of CNR) , Gianpietro Sechi (Medical School, University of Sassari) , Giuliano Siligardi (Diamond Light Source)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Biochimica Et Biophysica Acta (bba) - General Subjects

State: Published (Approved)
Published: May 2016
Diamond Proposal Number(s): 8034

Abstract: GFAP is the major intermediate filament protein in mature astrocytes. Its increased expression and aggregation was firstly associated to Alexander's disease, and successively in different neurological diseases including scrapie, Alzheimer's and Creutzfeld–Jacob diseases. Recently, ceftriaxone a multi-potent β-lactam antibiotic able to overcome the blood–brain barrier, successfully eliminated the cellular toxic effects of misfolded mutated GFAP, similarly to phenytoin sodium, in a cellular model of Alexander's disease and inhibited α-synuclein aggregation protecting PC12 cells from the exposure to 6-hydroxydopamine.

Journal Keywords: Ceftriaxone;

Subject Areas: Medicine, Biology and Bio-materials, Technique Development


Instruments: B23-Circular Dichroism

Discipline Tags:



Technical Tags: